A comparison of the biological activities of wild‐type and mutant p53

Tumorigenesis is characterized by a series of genetic alterations in both dominant oncogenes and tumor suppressor genes. A hallmark of tumor suppressor genes is that both alleles are generally altered during transformation, which usually represents a loss of function phenotype. The p53 tumor suppressor gene is the most frequently affected gene detected in human cancer. There is now growing evidence suggesting that mutation of p53 may involve not only a loss of function of wild‐type p53 activity but also a gain of function phenotype contributed by the mutant p53 protein. The study of the biological properties and functions of both wild‐type and mutant p53 is central to our understanding of human cancer. These properties and functions of wild‐type and mutant p53 will be compared and contrasted here and elsewhere within this thematic issue. In addition, the mechanisms of inactivation of p53 function, which include: 1) mutation, 2) inhibition by viral oncogene products, 3) inhibition by cellular regulators, and 4) alteration in subcellular localization, will be discussed.—Zambetti, G. P., Levine, A. J. A comparison of the biological activities of wild‐type and mutant p53. FASEB J. 7: 855‐865; 1993.

[1]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[2]  E. White,et al.  Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. , 1993, Genes & development.

[3]  C. Finlay,et al.  The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth , 1993, Molecular and cellular biology.

[4]  G. Zambetti,et al.  Wild-type p53 binds to the TATA-binding protein and represses transcription. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[6]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[7]  P. Friedman,et al.  Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. , 1992, Genes & development.

[8]  M. Subler,et al.  Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells , 1992, Journal of virology.

[9]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[10]  G. Wahl,et al.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.

[11]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Seizinger,et al.  Repression of the basal c-fos promoter by wild-type p53. , 1992, Nucleic acids research.

[13]  M. Remm,et al.  A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. , 1992, Oncogene.

[14]  T. Crook,et al.  Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53‐mediated repression of transcription. , 1992, The EMBO journal.

[15]  D. Lane,et al.  Abnormal expression of wild type p53 protein in normal cells of a cancer family patient , 1992, The Lancet.

[16]  A. Levine,et al.  Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Subler,et al.  Inhibition of viral and cellular promoters by human wild-type p53 , 1992, Journal of virology.

[18]  P. Friedman,et al.  Wild-type p53 activates transcription in vitro , 1992, Nature.

[19]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[20]  A. Levine,et al.  Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. , 1992, Genes & development.

[21]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[22]  J. Shay,et al.  A transcriptionally active DNA-binding site for human p53 protein complexes , 1992, Molecular and cellular biology.

[23]  R. Weichselbaum,et al.  Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. , 1992, The New England journal of medicine.

[24]  S. Friend,et al.  Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. , 1992, The New England journal of medicine.

[25]  A. Levine,et al.  A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Iavarone,et al.  Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Iggo,et al.  Mammalian p53 can function as a transcription factor in yeast. , 1992, Nucleic acids research.

[28]  T. Unger,et al.  p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. , 1992, The EMBO journal.

[29]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[30]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[31]  I. Pastan,et al.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. , 1992, Science.

[32]  J. E. Stenger,et al.  Formation of stable p53 homotetramers and multiples of tetramers , 1992, Molecular carcinogenesis.

[33]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression. , 1992, Science.

[34]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[35]  G. Lozano,et al.  Analysis of p53 mutants for transcriptional activity , 1991, Molecular and cellular biology.

[36]  A. Levine,et al.  p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. , 1991, Genes & development.

[37]  M. Yaniv,et al.  Wild-type p53 can down-modulate the activity of various promoters. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[38]  V. Rotter,et al.  Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. , 1991, Cancer research.

[39]  U. Santhanam,et al.  Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[41]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[42]  B. Vogelstein,et al.  Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication , 1991, Cell.

[43]  D. George,et al.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.

[44]  S. Tapscott,et al.  The MCK enhancer contains a p53 responsive element. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Milner,et al.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.

[46]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[47]  R. A. Metcalf,et al.  Mutational hot spot in the p53 gene in human hepatocellular carcinomas , 1991, Nature.

[48]  E. Appella,et al.  Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Levine,et al.  Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. , 1991, Genes & development.

[50]  J. Milner,et al.  Tumor suppressor p53: analysis of wild-type and mutant p53 complexes , 1991, Molecular and cellular biology.

[51]  M. Oren,et al.  Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein , 1991, Molecular and cellular biology.

[52]  R. Metcalf,et al.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas. , 1991, Nature.

[53]  V. Rotter,et al.  Mutant p53 proteins bind DNA abnormally in vitro. , 1991, Oncogene.

[54]  B. Vogelstein.  A deadly inheritance , 1990, Nature.

[55]  Yumay Chen,et al.  Genetic mechanisms of tumor suppression by the human p53 gene , 1990, Science.

[56]  V. Rotter,et al.  Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis , 1990, Molecular and cellular biology.

[57]  C. Dang,et al.  A potential transcriptional activation element in the p53 protein. , 1990, Oncogene.

[58]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[59]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[60]  B. Vogelstein,et al.  p53 functions as a cell cycle control protein in osteosarcomas , 1990, Molecular and cellular biology.

[61]  J. Milner,et al.  p53 is associated with p34cdc2 in transformed cells. , 1990, The EMBO journal.

[62]  S. Fields,et al.  Presence of a potent transcription activating sequence in the p53 protein. , 1990, Science.

[63]  G. Lozano,et al.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. , 1990, Science.

[64]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[65]  O. Halevy,et al.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.

[66]  P. Friedman,et al.  Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Bartek,et al.  Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. , 1990, Oncogene.

[68]  T. Maimets,et al.  p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. , 1990, Oncogene.

[69]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[70]  D. Lane,et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.

[71]  A. Levine,et al.  Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.

[72]  A. Harris,et al.  Increased expression of mutant forms of p53 oncogene in primary lung cancer , 1990, The Lancet.

[73]  B. Vogelstein.  Cancer. A deadly inheritance. , 1990, Nature.

[74]  M. Oren,et al.  Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[75]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[76]  A. Levine,et al.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation , 1989, Journal of virology.

[77]  M. Oren,et al.  Oligomerization of oncoprotein p53 , 1988, Journal of virology.

[78]  W. Deppert,et al.  DNA binding properties of murine p53. , 1988, Oncogene.

[79]  S. Benchimol,et al.  Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. , 1988, Oncogene.

[80]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[81]  U. Francke,et al.  Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line , 1987, Somatic cell and molecular genetics.

[82]  T. Soussi,et al.  Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. , 1987, Oncogene.

[83]  J. Milner,et al.  A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. , 1987, Oncogene.

[84]  J. Jenkins,et al.  Precise epitope mapping of the murine transformation‐associated protein, p53. , 1985, The EMBO journal.

[85]  J. Jenkins,et al.  Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53 , 1984, Nature.

[86]  D. Pim,et al.  Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. , 1984, The EMBO journal.

[87]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[88]  D. Goeddel,et al.  The amino acid sequence of murine p53 determined from a c-DNA clone. , 1984, Virology.

[89]  A. Levine,et al.  Growth regulation of a cellular tumour antigen, p53, in nontransformed cells , 1984, Nature.

[90]  A. Goldberg,et al.  Energy requirement for degradation of tumor-associated protein p53 , 1984, Molecular and cellular biology.

[91]  V. Rotter,et al.  Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species , 1984, Molecular and cellular biology.

[92]  D. Lane,et al.  Cellular proteins involved in SV40 transformation , 1983 .

[93]  A. Levine,et al.  Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells , 1982, Cell.

[94]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[95]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[96]  J. M. Oshorn.  Proc. Nat. Acad. Sei , 1978 .

[97]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.

[98]  L. Hayflick.  THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. , 1965, Experimental cell research.